Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
7.97
-0.05 (-0.62%)
Sep 5, 2025, 1:52 PM CST

Mercury Biopharmaceutical Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
3,3625,4987,7784,006--
Upgrade
Market Cap Growth
-33.13%-29.32%94.15%---
Upgrade
Enterprise Value
3,2105,2757,4653,937--
Upgrade
Last Close Price
7.9713.0518.709.87--
Upgrade
PS Ratio
13667.131107.827530.001494.92--
Upgrade
PB Ratio
13.3218.9420.0322.22--
Upgrade
P/TBV Ratio
13.6119.2420.1722.28--
Upgrade
EV/Sales Ratio
-1062.907226.331469.06--
Upgrade
Debt / Equity Ratio
0.190.160.110.240.19-1.43
Upgrade
Asset Turnover
0.000.010.000.02--
Upgrade
Quick Ratio
8.8112.0340.8919.791.500.28
Upgrade
Current Ratio
9.2112.6342.2120.152.300.32
Upgrade
Return on Equity (ROE)
-24.50%-14.90%-15.41%-32.76%-103.62%-
Upgrade
Return on Assets (ROA)
-13.11%-8.54%-8.55%-15.87%-49.15%-103.35%
Upgrade
Return on Capital (ROIC)
-13.72%-8.79%-8.73%-16.35%-52.74%-108.47%
Upgrade
Earnings Yield
-2.10%-0.92%-0.56%-0.78%--
Upgrade
FCF Yield
-1.77%-0.81%-0.71%-2.35%--
Upgrade
Buyback Yield / Dilution
4.54%-5.79%-5.83%-36.09%-165.94%-
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.